NCT06913816

Brief Summary

"Computer vision syndrome (CVS), refers to a range of eye and vision issues caused by extended use of computers, tablets, e-readers, and smartphones. Computer users experience visual symptoms, such as eyestrain, headaches, eye discomfort, dry eyes, double vision, and blurred vision, especially after long periods of looking at screens, whether up close or at a distance.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 20, 2025

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

March 29, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 6, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2025

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2026

Completed
Last Updated

April 6, 2025

Status Verified

March 1, 2025

Enrollment Period

3 months

First QC Date

March 29, 2025

Last Update Submit

March 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Computer Vision Syndrome (CVS-Q)

    The Computer Vision Syndrome Questionnaire (CVS-Q) assesses the frequency and intensity of 16 ocular and visual symptoms related to prolonged screen use, with a total score of 6 or more indicating CVS If the total score is ≥6 points, the individual is considered to suffer Computer Vision Syndrome

    12 Months

Study Arms (2)

Grouyp 1 (without blinking exercises).

ACTIVE COMPARATOR
Diagnostic Test: Grouyp 1 (without blinking exercises).

EXP group (Routine CVS treatment)

EXPERIMENTAL
Combination Product: EXP group (Routine CVS treatment)

Interventions

Group B (Control Group) The control group will continue receiving only the routine rehabilitation (without blinking exercises). Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.

Grouyp 1 (without blinking exercises).

"Group A (Experimental Group): Individuals in the Experimental group will receive Routine CVS treatment with optimized blinking exercise. Routine rehabilitation includes the 20-20-20 rule, blue light-blocking glasses, and polyvinyl eye drops. The blinking exercise involved the individuals looking at an object 6 meters away for 5 seconds, followed by complete eyelid closure for 5 seconds. This cycle was repeated for 5 minutes, twice a day."

EXP group (Routine CVS treatment)

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Individuals aged 18-40 years who work on computers or digital devices for at least 3 to 6 hours daily.
  • Both Male and Female.
  • Individuals who could undergo a complete ocular examination.
  • Presence of symptoms consistent with digital eye strain.
  • Presented with eye complaints such as eye fatigue, burning, irritation, redness, and blurred vision due to long-term computer or digital screen use.
  • Symptoms worsened during exposure to digital screen light.

You may not qualify if:

  • Use of medications that might influence tear production or ocular surface status (e.g., antihistamines, antidepressants).
  • Diagnosed neurological or systemic conditions that impact vision or blink patterns (e.g., Parkinson's disease, multiple sclerosis).
  • Individual's with a history of ocular surface diseases such as conjunctivitis or keratitis.
  • History of any psychiatric diagnosis."

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ramzan Eye Care and Optix Khudian Khas

Kasur, Punjab Province, Pakistan

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 29, 2025

First Posted

April 6, 2025

Study Start

March 20, 2025

Primary Completion

June 20, 2025

Study Completion

February 20, 2026

Last Updated

April 6, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations